Founder of Biosplice Therapeutics, Osman Kibar

Osman Kibar is the founder of Biosplice Therapeutics, formerly known as Samumed which is a private biopharmaceutical business situated in San Diego, California. It’s being researched and developed in the medical field for tissue regeneration.

Dr. Kibar is an entrepreneur and inventor who has founded a number of successful businesses. Genoptix, which was eventually acquired by Novartis in 2011, was founded by him. Dr. Kibar was also a Co-Founder of E-Tenna, whose wireless antenna assets were acquired by Titan and whose thermal management of microprocessor capabilities were acquired by Intel. Dr. Kibar earned his MS and Ph.D. in Biophotonics and Optoelectronics from UC San Diego, as well as a BS in Electrical Engineering from Caltech and a BA in Mathematical Economics from Pomona College.

Biosplice Therapeutics was founded in 2008 and has spent the majority of its time operating under the radar. It emerged from the shadows in 2016 with a $220 million war fund and a pipeline of anti-aging pharmaceuticals, thanks to investors including Ikea’s private venture arm and some extremely affluent individuals. Novel components of the Wnt signalling system are being targeted by its products under development. The company is working on remedies for a variety of ailments, with its osteoarthritis programme being the most advanced.

Their scientific platform is built on biological findings that govern tissue specialisation and allow tiny chemicals to be used to selectively eradicate toxic proteins. By targeting the CLK/DYRK family kinases, their groundbreaking discoveries in Wnt pathway modulation revealed the enormous therapeutic potential of alternative splicing.

Omar’s goal with Biosplice is to restore health by providing first-in-class medicines that use alternative splicing.